Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015

Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries

Ekaterina V. KurbatovaComments to Author , Tracy Dalton, Julia Ershova, Thelma E. Tupasi, Janice Campos Caoili, Martie L. van der Walt, Charlotte L. Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Laura E. Via, HeeJin Kim, Somsak Akksilp, Boris Y. Kazennyy, Grigory V. Volchenkov, Ruwen Jou, Kai Kliiman, Olga V. Demikhova, and J. Peter Cegielski
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, T. Dalton, J. Ershova, J. Campos Caoili, C. Kvasnovsky, J.P. Cegielski); Tropical Disease Foundation, Manila, the Philippines (T. Tupasi, J. Campos Caoili); Medical Research Council, Pretoria, South Africa (M. Van Der Walt, C. Kvasnovsky); National Institute of Health, Lima, Peru (M. Yagui); Socios en Salud Sucursal Perú, Lima (J. Bayona, C. Contreras); Riga East University Hospital Centre of Tuberculosis and Lung Diseases, Riga, Latvia (V. Leimane); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA (L.E. Via); University of Cape Town, Cape Town, South Africa (L.E. Via):; Korean Institute of TB, Seoul, South Korea (H. Kim); Ministry of Public Health, Bangkok, Thailand (S. Akksilp); Orel Oblast Tuberculosis Dispensary, Orel, Russia (B.Y. Kazennyy); Vladimir Oblast Tuberculosis Dispensary, Vladimir, Russia (G.V. Volchenkov); Taiwan Centers for Disease Control, Taipei, Taiwan (R. Jou); Tartu University Hospital, Tartu, Estonia (K. Kliiman); Russian Academy of Medical Sciences, Moscow, Russia (O.V. Demikhova)

Main Article

Table 3

Resistance patterns of drugs effective in vitro for multidrug-resistant tuberculosis

Total, N = 1,254 Candidate effective drugs
Short regimen, FQ-S and SLI-S, n = 952 BDQ-containing regimen
Combined FQ-R or SLI-R,† n = 302 FQ-R only, 
n = 73 SLI-R only, 
n = 155 XDR, 
n = 74
Median 5 5 3 4 3 2
Interquartile range 4–6 5–6 2–4 4–5 3–4 1–2
Range 0–7 3–7 0–6 2–6 1–5 0–4

*Drug susceptibility test results were analyzed for 7 drugs: high-dose isoniazid, ethambutol, FQ, aminoglycoside, capreomycin, ethionamide, and para-aminosalicylic acid; BDQ, bedaquiline; FQ, fluoroquinolone; R, resistant; S, susceptible; SLI, second-line injectable drug; XDR, extensively drug-resistant.
†Includes FQ-R only, SLI-R only, and XDR cases combined.

Main Article

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.